Infliximab drug monitoring
Immunology
Sample and container requirements
Serum Li Hep plasma
Minimum volume required
4 ml Blood
Special requirements
none
Patient preparation
None
Sample viability
Store at 4oC prior to sending to referral lab
Turnaround time
21 days
Reference range
Suggested target drug concentrations for intravenous infliximab in the treatment of IBD: Induction/post induction Week 2 Infliximab concentration to target 20-25 ug/mL Week 6 Infliximab concentration to target 15-20 ug/mL Week 14 Infliximab concentration to target 7-10 ug/mL Maintenance Infliximab concentration to target 7-10 ug/mL
Clinical guidance
Measurement of Infliximab is a useful tool in the management of patients who fail to respond ( primary failure) or lose response ( secondary failure) to treatment. Monitoring drug levels allows for a personalised approach to drug optimisation by appropriate dose escalation/de-escalation or drug switching/withdrawal. Measured as part of Infliximab profile which includes anti drug antibodies. Assay also measures biosimilars Remsima and Inflectra.
Notes
Synnovis
Images to go here
This information was last updated on 19 August 2026